Page 42 - TD-3-4

Tumor Discovery HIF1α treatments in renal cell carcinoma

11. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible doi: 10.1007/s12032-018-1217-1
factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer 22. Drugs.com. Sutent (Sunitinib Malate) FDA Approval History.
Res. 2007;13(24):7388-7393.
Available from: https://www.drugs.com/history/sutent.html
doi: 10.1158/1078-0432.CCR-07-0411 [Last accessed on 2024 Jul 14].
12. Shen C, Beroukhim R, Schumacher SE, et al. Genetic and 23. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus
functional studies implicate HIF1α as a 14q kidney cancer interferon alfa in metastatic renal-cell carcinoma. N Engl J
suppressor gene. Cancer Discov. 2011;1(3):222-235. Med. 2007;356(2):115-124.
doi: 10.1158/2159-8290.CD-11-0098 doi: 10.1056/NEJMoa065044
13. Xu K, Ding Q, Fang Z, et al. Silencing of HIF-1α suppresses 24. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug
tumorigenicity of renal cell carcinoma through induction of approval summary: Bevacizumab plus interferon for advanced
apoptosis. Cancer Gene Ther. 2010;17(3):212-222. renal cell carcinoma. Oncologist. 2010;15(1):104-111.
doi: 10.1038/cgt.2009.66 doi: 10.1634/theoncologist.2009-0250
14. Tassoudi A, Stefanidis I, Eleftheriadis T, Tzortzis V, 25. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab Plus
Tassoudis V, Ioannou M. Study of hypoxia induced factor- interferon alfa compared with interferon alfa monotherapy
1alpha (HIF-1A) and carbonic anhydrase 9 (CAIX) in Clear in patients with metastatic renal cell carcinoma: CALGB
Cell Renal Cell Carcinoma (ccRCC). Arch Nephrol Urol. 90206. J Clin Oncol. 2008;26(33):5422-5428.
2021;4(2):50-62.
doi: 10.1200/JCO.2008.16.9847
doi: 10.26502/anu.2644-2833036
26. Gupta S, Spiess PE. The prospects of pazopanib in advanced
15. Fallah J, Rini BI. HIF inhibitors: Status of current clinical renal cell carcinoma. Ther Adv Urol. 2013;5(5):223-232.
development. Curr Oncol Rep. 2019;21(1):6.
doi: 10.1177/1756287213495099
doi: 10.1007/s11912-019-0752-z
27. Kim JH, Park I, Lee JL. Pazopanib versus sunitinib for
16. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist the treatment of metastatic renal cell carcinoma patients
of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor with poor-risk features. Cancer Chemother Pharmacol.
cell growth. Mol Cancer Ther. 2008;7(11):3598-3608. 2016;78(2):325-332.
doi: 10.1158/1535-7163.MCT-08-0510 doi: 10.1007/s00280-016-3093-8
17. Costa LJ, Drabkin HA. Renal cell carcinoma: New 28. Tyler T. Axitinib: Newly approved for renal cell carcinoma.
developments in molecular biology and potential for J Adv Pract Oncol. 2012;3(5):333-335.
targeted therapies. Oncologist. 2007;12(12):1404-1415.
doi: 10.6004/jadpro.2012.3.5.7
doi: 10.1634/theoncologist.12-12-1404
29. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib
18. Drugs.com. Nexavar FDA Approval History. Available versus sunitinib for advanced renal-cell carcinoma. N Engl J
from: https://www.drugs.com/history/nexavar. Med. 2019;380(12):1103-1115.
html#:~:text=fda%20approved%3a%20yes%20 doi: 10.1056/NEJMoa1816047
%28first%20approved%20december%2020%2c%20
2005%29,for%3a%20renal%20cell%20carcinoma%2c%20 30. Center for Drug Evaluation and Research. FDA Grants
hepatocellular%20carcinoma%2c%20thyroid%20cancer Regular Approval to Cabometyx for First-Line Treatment
[Last accessed on 2024 Jul 14]. of Advanced Renal Cell Carcinoma. U.S. Food and Drug
Administration, FDA. Available from: https://www.
19. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in fda.gov/drugs/resources-information-approved-drugs/
advanced clear-cell renal-cell carcinoma. N Engl J Med. fda-grants-regular-approval-cabometyx-first-line-
2007;356(2):125-134.
treatment-advanced-renal-cell-carcinoma#:~:text=on%20
doi: 10.1056/NEJMoa060655 december%2019%2c%202017%2c%20the,renal%20cell%20
carcinoma%20(rcc) [Last accessed on 2024 Jul 14].
20. Kathuria-Prakash N, Drolen C, Hannigan CA, Drakaki A.
Immunotherapy and metastatic renal cell carcinoma: 31. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib
A review of new treatment approaches. Life (Basel). versus sunitinib as initial targeted therapy for patients with
2021;12(1):24. metastatic renal cell carcinoma of poor or intermediate
risk: The alliance A031203 CABOSUN trial. J Clin Oncol.
doi: 10.3390/life12010024
2017;35(6):591-597.
21. Wiechno P, Kucharz J, Sadowska M, et al. Contemporary
treatment of metastatic renal cell carcinoma. Med Oncol. doi: 10.1200/JCO.2016.70.7398
2018;35(12):156. 32. Center for Drug Evaluation and Research. FDA D.I.S.C.O.

Volume 3 Issue 4 (2024) 7 doi: 10.36922/td.4346